Beyond the initial prescription, what happens next matters even more
Type 3 diabetes is a term used to underscore a growing body of evidence that Alzheimers involves insulin resistance in the brain, impaired glucose metabolism, mitochondrial dysfunction, chronic inflammation, and oxidative stressmuch like in type 2 diabetes
The bottom line Based on the evidence so far, it seems likely that GLP-1 agonists will eventually be approved to treat some conditions beyond diabetes and obesity, even if they dont deliver on every potential benefit
These frequently asked questions may help
The establishment of this pathological mechanism has undergone extensive exploration: from the initial report by Burghen et al
As the industry scales, Ypsomed is ensuring that sustainability keeps pace, proving that innovation and environmental stewardship can go hand in hand